TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8560291

Group type: EXPERIMENTAL
Intervention: Home visits offering social support to high-risk women
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Home visits providing medical care to women with complications
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Home visits (general)
Number of subjects: 8
Study: 1770067

Group type: EXPERIMENTAL
Intervention: Physical activity maintained (G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical activity restricted (R)
Number of subjects: 0
Study: 7104136

Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia with enflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: i.v. fentanyl
Number of subjects: 0
Study: 30410145

Group type: EXPERIMENTAL
Intervention: 8-week training on Biodex balance system
Number of subjects: 18

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison between groups post-intervention
Number of subjects: 18
Study: 27739405

Group type: EXPERIMENTAL
Intervention: Brain computer interface (BCI) controlled functional electrical stimulation (FES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive functional electrical stimulation (FES)
Number of subjects: 12
Study: 25164450

Group type: EXPERIMENTAL
Intervention: Glucose group (acetated Ringer solution with 1.5% glucose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (acetated Ringer solution without glucose)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Glucose group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 23140090

Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 20148656

Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015%
Number of subjects: 38

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both Tafluprost and Latanoprost
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tafluprost
Number of subjects: 38

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 38
Study: 18560239

Group type: EXPERIMENTAL
Intervention: Graded exercise protocol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 12
Study: 16279144

Group type: EXPERIMENTAL
Intervention: Treatment effects estimated within each trial assuming a common treatment effect across trials.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Random effects methods used in analyses.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Subgrouping patients to investigate covariate-treatment interactions.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Data inclusion from randomized patients.
Number of subjects: 44
Study: 12460526

Group type: EXPERIMENTAL
Intervention: Multicomponent stage-matched intervention
Number of subjects: 2324

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2324
Study: 9788003

Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disulfiram 500 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine 1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine 2 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for cocaine administration
Number of subjects: 0
Study: 7637352

Group type: EXPERIMENTAL
Intervention: alpha‐stat management
Number of subjects: 316

Group type: COMPARATOR
Intervention: pH‐stat management
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Coronary bypass group
Number of subjects: 316

Group type: COMPARATOR
Intervention: Major surgery cohort
Number of subjects: 316
Study: 2198928

Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 27
Study: 832447

Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC) 0.022 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC) 0.044 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diazepam 0.157 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (Ringer's lactate)
Number of subjects: 10
Study: 31042670

Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy control diet
Number of subjects: 70
Study: 27712113

Group type: EXPERIMENTAL
Intervention: Palonosetron IV (0.75 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Palonosetron IV (0.75 mg) and hydroxyzine PO (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26027624

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) cardiac rehabilitation program, 3 weekly sessions for 12 weeks.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Full-body stretching exercises (control group), 3 weekly sessions for 12 weeks.
Number of subjects: 61
Study: 23568480

Group type: EXPERIMENTAL
Intervention: uPA/PAI-1 testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: All-CTX strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-CTX strategy
Number of subjects: 0
Study: 21886066

Group type: EXPERIMENTAL
Intervention: Balneotherapy and physiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 60
Study: 19054177

Group type: EXPERIMENTAL
Intervention: Psychosocial group nursing intervention
Number of subjects: 235
Study: 17245770

Group type: EXPERIMENTAL
Intervention: VAS-based method
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard method
Number of subjects: 25
Study: 15301901

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium administration to replenish low serum magnesium concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate for treatment of torsade de pointes
Number of subjects: 0
Study: 11702324

Group type: EXPERIMENTAL
Intervention: Hydromorphone 283 micrograms (low dose, LD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hydromorphone 566 micrograms (high dose, HD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of hydromorphone 283 micrograms and metamizole 50 mg (low dose hydromorphone + metamizole, LM)
Number of subjects: 120
Study: 9135694

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7756153

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MMF)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Betamethasone-17-valerate (BM-17-valerate)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 15
Study: 2218190

Group type: EXPERIMENTAL
Intervention: Combination of therapies with independent activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of therapy to patients in a disease-free (remission) state
Number of subjects: 0
Study: 75392

Group type: EXPERIMENTAL
Intervention: Flufenamic acid (200 mg three times a day)
Number of subjects: 44
Study: 31842394

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 28337705

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids plus antioxidant vitamin supplementation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Supplemented/POAF
Number of subjects: 2
Study: 23853211

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Flexible Spectral Imaging Chromoendoscopy (FICE)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: White Light (WL)
Number of subjects: 1650
Study: 22618211

Group type: EXPERIMENTAL
Intervention: Seprafilm-wrapped ileostomies
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional ileostomies
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Seprafilm stoma patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional stoma patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 20139661

Group type: EXPERIMENTAL
Intervention: Regular physical exercise for 12 months
Number of subjects: 105
Study: 18486224

Group type: EXPERIMENTAL
Intervention: Optic nerve decompression surgery (n = 127)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Careful follow‐up (n = 131)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Not applicable (fellow nonstudy eyes)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Not applicable (change in visual acuity)
Number of subjects: 418
Study: 16162259

Group type: EXPERIMENTAL
Intervention: Single-fibre EMG (SFEMG) in migraine patients with aura
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Single-fibre EMG (SFEMG) in migraine patients with visual aura
Number of subjects: 26

Group type: COMPARATOR
Intervention: Single-fibre EMG (SFEMG) in healthy controls
Number of subjects: 26

Group type: COMPARATOR
Intervention: Single-fibre EMG (SFEMG) in migraine without aura
Number of subjects: 26
Study: 12552492

Group type: EXPERIMENTAL
Intervention: Low-calorie normoproteinic diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual dietary intake (Control)
Number of subjects: 30
Study: 10379482

Group type: EXPERIMENTAL
Intervention: Interferon-alfa (6 MU t.i.w.) plus ribavirin (1000 mg/daily)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Interferon-alfa alone (6 MU t.i.w.)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Interferon-alfa plus ribavirin
Number of subjects: 88
Study: 7675230

Group type: EXPERIMENTAL
Intervention: Tegretol-XR 200-mg tablets every 12 hours
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tegretol 200-mg tablets three or four times daily
Number of subjects: 96
Study: 2275837

Group type: EXPERIMENTAL
Intervention: Minimal composite restoration
Number of subjects: 103

Group type: COMPARATOR
Intervention: Amalgam restoration
Number of subjects: 103

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 103
Study: 7222869

Group type: EXPERIMENTAL
Intervention: Intracervically applied Prostaglandin F2 alpha Gel
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 124
Study: 31837079

Group type: EXPERIMENTAL
Intervention: DISCO
Number of subjects: 130
Study: 30730438

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy in patients with intracranial pressure monitoring
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Single occurrence of mean arterial pressure < 65 mm Hg
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure > 180 mm Hg
Number of subjects: 882
Study: 27334444

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control condition (treatment as usual + online psychoeducation about depression)
Number of subjects: 260
Study: 25827850

Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation (BSC) intervention delivered by mental health specialists
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: BSC intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: BSC intervention and usual GP care
Number of subjects: 97
Study: 23374729

Group type: EXPERIMENTAL
Intervention: 0.5% PRO2000 gel
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 544
Study: 21419286

Group type: EXPERIMENTAL
Intervention: IN ketorolac
Number of subjects: 22

Group type: COMPARATOR
Intervention: IN placebo
Number of subjects: 22
Study: 19165757

Group type: EXPERIMENTAL
Intervention: Meaning-centered intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Waiting-list group (Control)
Number of subjects: 109
Study: 17823418

Group type: EXPERIMENTAL
Intervention: Twice-weekly strength training for 2 years
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard care (brochures recommending aerobic exercise)
Number of subjects: 164
Study: 15520425

Group type: EXPERIMENTAL
Intervention: Educational video about colorectal cancer and screening options (n = 450)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Usual care (n = 488)
Number of subjects: 938
Study: 11116286

Group type: EXPERIMENTAL
Intervention: Tedisamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 0
Study: 9491571

Group type: EXPERIMENTAL
Intervention: Environmental support at encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental support at retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 0
Study: 8173852

Group type: EXPERIMENTAL
Intervention: 24 h bed rest following intra-articular steroid injection
Number of subjects: 91

Group type: COMPARATOR
Intervention: Routine outpatient injections (no rest)
Number of subjects: 91
Study: 3224402

Group type: EXPERIMENTAL
Intervention: Piperacillin + Amikacin (P + A)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cefotaxime + Amikacin (C + A)
Number of subjects: 71
Study: 31410518

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 158

Group type: COMPARATOR
Intervention: TVT-Abbrevo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study: 29975624

Group type: EXPERIMENTAL
Intervention: Progression-Free Survival (PFS)
Number of subjects: 7507

Group type: EXPERIMENTAL
Intervention: Progression-Free Survival at 24 months (PFS24)
Number of subjects: 7507

Group type: EXPERIMENTAL
Intervention: Surrogate threshold effect for PFS
Number of subjects: 7507

Group type: EXPERIMENTAL
Intervention: Surrogate threshold effect for PFS24
Number of subjects: 7507
Study: 26997308

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-guided approach
Number of subjects: 80
Study: 24018781

Group type: EXPERIMENTAL
Intervention: Olmesartan/amlodipine combination 20/5 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Olmesartan 20 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 276
Study: 23446066

Group type: EXPERIMENTAL
Intervention: Education/advice plus an 8-week pedometer-driven walking program (EWP, n=40)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Education/advice (E, n=17)
Number of subjects: 57
Study: 20957980

Group type: EXPERIMENTAL
Intervention: Ipilimumab (0.3, 3, or 10 mg/kg)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Ipilimumab (phase III study)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Ipilimumab (all doses)
Number of subjects: 453
Study: 19025266

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 400
Study: 16368302

Group type: EXPERIMENTAL
Intervention: Resynchronization by LV pacing alone
Number of subjects: 29
Study: 12590027

Group type: EXPERIMENTAL
Intervention: Education and exercise training programs
Number of subjects: 92
Study: 10916104

Group type: EXPERIMENTAL
Intervention: Vitamin E-modified, regenerated cellulose (CL-E) membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polysulfone (PS) membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cellulosic membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cellulose membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CL-E membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CL-E or synthetic membrane
Number of subjects: 0
Study: 8750567

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 107

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 107
Study: 1556836

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of BCG Tokyo 172 strain (80 mg in 40 ml saline, once a week for 8 weeks)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with BCG (40 mg in 40 ml saline, monthly for 12 months)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group without any prophylactic instillation
Number of subjects: 157
Study: 3901269

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-FU
Number of subjects: 0
Study: 31367384

Group type: EXPERIMENTAL
Intervention: SeptiFast (SF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional blood cultures (BCs)
Number of subjects: 200
Study: 28940961

Group type: EXPERIMENTAL
Intervention: Continuation of metformin (MF+)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Withholding metformin (MF-)
Number of subjects: 70
Study: 28053789

Group type: EXPERIMENTAL
Intervention: Capsaicin cream applied around participants' ankle during locomotor training (Pain group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (always pain-free)
Number of subjects: 0
Study: 24615429

Group type: EXPERIMENTAL
Intervention: High-dose omega-3 ethyl esters (n-3 PUFA), 2-4 g daily for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluvastatin and omega-3 ethyl esters (n-3 PUFA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study: 23039306

Group type: EXPERIMENTAL
Intervention: VIH‐TAVIE™ intervention (web application with four interactive computer sessions of 20 to 30 minutes each)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (list of websites of interest)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: VIH‐TAVIE™ intervention
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 232
Study: 20651615

Group type: EXPERIMENTAL
Intervention: Docetaxel monotherapy (60 mg/m, day 1, q3 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination of docetaxel (40 mg/m, day 1, q3 weeks) and S-1 (80 mg/m, days 1-15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Docetaxel monotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination of docetaxel and S-1
Number of subjects: 60
Study: 17560879

Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin (10/10, 10/20, 10/40, or 10/80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin (10, 20, 40, or 80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin (10, 20, 40, or 80 mg)
Number of subjects: 0
Study: 16018379

Group type: EXPERIMENTAL
Intervention: Laxomucil (2 sachets, 3.26 g plantago ovata, twice daily for 20 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glycerin oil (control group)
Number of subjects: 60
Study: 11755835

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% in the morning and placebo in the evening
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Indomethacin 25 mg four times a day
Number of subjects: 20
Study: 9840561

Group type: EXPERIMENTAL
Intervention: Passive gravity outflow
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct connection of the outflow to wall suction
Number of subjects: 40
Study: 8136666

Group type: EXPERIMENTAL
Intervention: Gamolenic acid (evening primrose oil)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (liquid paraffin)
Number of subjects: 56
Study: 2914474

Group type: EXPERIMENTAL
Intervention: Nasal oxygen therapy at 2 L/min
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nasal air therapy
Number of subjects: 17
Study: 30317291

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous dexamethasone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg dexamethasone infiltrated into the peritonsillar regions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 mL of 0.5% bupivacaine infiltration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Peritonsillar saline infiltration
Number of subjects: 60
Study: 28259181

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post‐tetanic count of 1‐2)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 96
Study: 25819584

Group type: EXPERIMENTAL
Intervention: NVP-ART
Number of subjects: 22
Study: 24968533

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 40
Study: 20797686

Group type: EXPERIMENTAL
Intervention: Experimental pairs presented alone or with filler pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental pairs with variability in congruity of components
Number of subjects: 0
Study: 18432173

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy followed by drug-eluting stent implantation (Rota-DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-eluting stent implantation alone (DES)
Number of subjects: 0
Study: 16150034

Group type: EXPERIMENTAL
Intervention: Computer-based learning (CBL) programme covering cardiovascular drug therapy (n = 70)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (traditional teaching) (n = 97)
Number of subjects: 167
Study: 12829911

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) monotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Azathioprine + prednisolone dual therapy
Number of subjects: 25
Study: 10827214

Group type: EXPERIMENTAL
Intervention: 200 microg folate/d
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 415 microg folate/d (as diet plus FA or a combination of FA and OJ)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Moderately folate-deplete diet (118 microg/d)
Number of subjects: 33
Study: 8878711

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 2071268

Group type: EXPERIMENTAL
Intervention: Imidazole salicylate (750 mg t.i.d.)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg t.i.d.)
Number of subjects: 31
Study: 6191495

Group type: EXPERIMENTAL
Intervention: Salicylic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tretinoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional anti-acne medications (other than salicylic acid and tretinoin)
Number of subjects: 0